{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:01:06Z","timestamp":1794888066555,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7711","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1038\/s41586-018-0217-9","type":"journal-article","created":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T10:28:28Z","timestamp":1528712908000},"page":"540-546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":556,"title":["Targeted therapy in patients with PIK3CA-related overgrowth syndrome"],"prefix":"10.1038","volume":"558","author":[{"given":"Quitterie","family":"Venot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smail Hadj","family":"Rabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laureline","family":"Berteloot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Ladraa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Hoguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Boccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Sarnacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Boddaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Pannier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sato","family":"Magassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junna","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Knebelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Merville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Grenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Cormier-Daire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bole-Feysot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Soupre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Lyonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Sadoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotfi","family":"Slimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chaussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Laroche-Raynaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Guibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Broissand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Amiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Legendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Terzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Canaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,13]]},"reference":[{"key":"217_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrm3290","volume":"13","author":"B Vanhaesebroeck","year":"2012","unstructured":"Vanhaesebroeck, B., Stephens, L. & Hawkins, P. PI3K signalling: the path to discovery and understanding. Nat. Rev. Mol. Cell Biol. 13, 195\u2013203 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"217_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0092-8674(92)90166-A","volume":"70","author":"ID Hiles","year":"1992","unstructured":"Hiles, I. D. et al. Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell 70, 419\u2013429 (1992).","journal-title":"Cell"},{"key":"217_CR3","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1126\/science.279.5351.710","volume":"279","author":"L Stephens","year":"1998","unstructured":"Stephens, L. et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279, 710\u2013714 (1998).","journal-title":"Science"},{"key":"217_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning, B. D. & Toker, A. AKT\/PKB signaling: navigating the network. Cell 169, 381\u2013405 (2017).","journal-title":"Cell"},{"key":"217_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ajmg.a.36836","volume":"167A","author":"KM Keppler-Noreuil","year":"2015","unstructured":"Keppler-Noreuil, K. M. et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am. J. Med. Genet. A. 167A, 287\u2013295 (2015).","journal-title":"Am. J. Med. Genet. A."},{"key":"217_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/ajmg.a.36552","volume":"164A","author":"KM Keppler-Noreuil","year":"2014","unstructured":"Keppler-Noreuil, K. M. et al. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am. J. Med. Genet. A. 164A, 1713\u20131733 (2014).","journal-title":"Am. J. Med. Genet. A."},{"key":"217_CR7","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.05.006","volume":"90","author":"KC Kurek","year":"2012","unstructured":"Kurek, K. C. et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am. J. Hum. Genet. 90, 1108\u20131115 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"217_CR8","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/nm.3313","volume":"19","author":"G Canaud","year":"2013","unstructured":"Canaud, G. et al. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat. Med. 19, 1288\u20131296 (2013).","journal-title":"Nat. Med."},{"key":"217_CR9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550\u2013562 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"217_CR10","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1016\/j.bmcl.2013.05.007","volume":"23","author":"P Furet","year":"2013","unstructured":"Furet, P. et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg. Med. Chem. Lett. 23, 3741\u20133748 (2013).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"217_CR11","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-13-0865","volume":"13","author":"C Fritsch","year":"2014","unstructured":"Fritsch, C. et al. Characterization of the novel and specific PI3K\u03b1 inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol. Cancer Ther. 13, 1117\u20131129 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"217_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","volume":"23","author":"IA Mayer","year":"2017","unstructured":"Mayer, I. A. et al. A phase Ib study of alpelisib (BYL719), a PI3K\u03b1-specific inhibitor, with letrozole in ER+\/HER2\u2212 metastatic breast cancer. Clin. Cancer Res. 23, 26\u201334 (2017).","journal-title":"Clin. Cancer Res."},{"key":"217_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","volume":"139","author":"L Srinivasan","year":"2009","unstructured":"Srinivasan, L. et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573\u2013586 (2009).","journal-title":"Cell"},{"key":"217_CR14","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1128\/MCB.16.8.4117","volume":"16","author":"A Klippel","year":"1996","unstructured":"Klippel, A. et al. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Mol. Cell. Biol. 16, 4117\u20134127 (1996).","journal-title":"Mol. Cell. Biol."},{"key":"217_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1006\/dbio.2002.0597","volume":"244","author":"S Hayashi","year":"2002","unstructured":"Hayashi, S. & McMahon, A. P. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation\/inactivation in the mouse. Dev. Biol. 244, 305\u2013318 (2002).","journal-title":"Dev. Biol."},{"key":"217_CR16","doi-asserted-by":"publisher","first-page":"332ra43","DOI":"10.1126\/scitranslmed.aad9982","volume":"8","author":"SD Castillo","year":"2016","unstructured":"Castillo, S. D. et al. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans. Sci. Transl. Med. 8, 332ra43 (2016).","journal-title":"Sci. Transl. Med."},{"key":"217_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ydbio.2015.04.022","volume":"404","author":"LM Hare","year":"2015","unstructured":"Hare, L. M. et al. Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects. Dev. Biol. 404, 14\u201326 (2015).","journal-title":"Dev. Biol."},{"key":"217_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.87623","volume":"1","author":"G Mirzaa","year":"2016","unstructured":"Mirzaa, G. et al. PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. JCI Insight 1, e87623 (2016).","journal-title":"JCI Insight"},{"key":"217_CR19","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1096\/fj.14-262782","volume":"29","author":"KM Kinross","year":"2015","unstructured":"Kinross, K. M. et al. Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly. FASEB J. 29, 1426\u20131434 (2015).","journal-title":"FASEB J."},{"key":"217_CR20","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/pbc.23124","volume":"57","author":"AM Hammill","year":"2011","unstructured":"Hammill, A. M. et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr. Blood Cancer 57, 1018\u20131024 (2011).","journal-title":"Pediatr. Blood Cancer"},{"key":"217_CR21","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500\u20131508 (2006).","journal-title":"Cancer Res."},{"key":"217_CR22","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1126\/science.1715094","volume":"253","author":"J Heitman","year":"1991","unstructured":"Heitman, J., Movva, N. R. & Hall, M. N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253, 905\u2013909 (1991).","journal-title":"Science"},{"key":"217_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1590\/S0036-36342002000400009","volume":"44","author":"E Velarde-Jurado","year":"2002","unstructured":"Velarde-Jurado, E. & Avila-Figueroa, C. [Evaluation of the quality of life]. Salud Publica Mex. 44, 349\u2013361 (2002).","journal-title":"Salud Publica Mex."},{"key":"217_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649\u2013655 (1982).","journal-title":"Am. J. Clin. Oncol."},{"key":"217_CR25","first-page":"2033","volume":"2010","author":"A Seluanov","year":"2010","unstructured":"Seluanov, A., Vaidya, A. & Gorbunova, V. Establishing primary adult fibroblast cultures from rodents. J. Vis. Exp. 2010, 2033 (2010).","journal-title":"J. Vis. Exp."},{"key":"217_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2002-3-7-research0034","volume":"3","author":"J Vandesompele","year":"2002","unstructured":"Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034 (2002).","journal-title":"Genome Biol."},{"key":"217_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1056\/NEJMoa1312890","volume":"371","author":"G Canaud","year":"2014","unstructured":"Canaud, G. et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N. Engl. J. Med. 371, 303\u2013312 (2014).","journal-title":"N. Engl. J. Med."}],"updated-by":[{"DOI":"10.1038\/s41586-019-1109-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41586-018-0217-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41586-018-0217-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41586-018-0217-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:46:53Z","timestamp":1684604813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-018-0217-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":27,"journal-issue":{"issue":"7711","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["217"],"URL":"https:\/\/doi.org\/10.1038\/s41586-018-0217-9","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733442703.793548824","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.733442703.793547496","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"1 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The \u2018Competing interests\u2019 statement of this Article has been updated; see accompanying Amendment for further details.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A patent application (WO2017140828A1) has been filed by INSERM (Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale), Centre National De La Recherche Scientifique (CNRS), Universit\u00e9 Paris Descartes, and Assistance Publique-H\u00f4pitaux De Paris (AP-HP) for the use of BYL719 (alpelisib) in the treatment of PIK3CA-related overgrowth spectrum (PROS\/CLOVES syndrome). G.C. is the inventor.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}